Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study
Objective. To compare efficacy and safety of intravenous continuous infusion of oxycodone with morphine in patients with cancer pain. Methods. A 5-day, randomized, open-label, exploratory study at 6 sites in the Republic of Korea. Sixty-six adults aged ≥19 years with moderate-to-severe cancer pain (...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Pain Research and Management |
| Online Access: | http://dx.doi.org/10.1155/2017/9741729 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560776351580160 |
|---|---|
| author | Kyung-Hee Lee Jung-Hun Kang Ho-Suk Oh Moon-Ki Choi Byoung-Yong Shim Young-Jun Eum Hye-Jeong Park Jin-Hyong Kang |
| author_facet | Kyung-Hee Lee Jung-Hun Kang Ho-Suk Oh Moon-Ki Choi Byoung-Yong Shim Young-Jun Eum Hye-Jeong Park Jin-Hyong Kang |
| author_sort | Kyung-Hee Lee |
| collection | DOAJ |
| description | Objective. To compare efficacy and safety of intravenous continuous infusion of oxycodone with morphine in patients with cancer pain. Methods. A 5-day, randomized, open-label, exploratory study at 6 sites in the Republic of Korea. Sixty-six adults aged ≥19 years with moderate-to-severe cancer pain (Numeric Rating Scale [NRS] ≥ 4) were enrolled. The study group received intravenous (IV) oxycodone, and the comparator group received IV morphine which were titrated depending on pain intensity. The efficacy endpoint is change in average NRS score from baseline to Day 5. Other assessments included worst, current, and average pain intensity; patient satisfaction; medication dose; and adverse events. Results. Both groups achieved >50% reduction in average pain intensity: from “moderate” at baseline (oxycodone versus morphine: 6.0 ± 1.8 versus 5.9 ± 1.4) to “mild” at Day 5 (2.5 ± 1.8 versus 2.8 ± 1.6). While this reduction was similar between groups (3.5 ± 2.2 versus 3.1 ± 1.8, P value = 0.562), oxycodone achieved faster pain relief (average pain: 3.0 ± 1.6 versus 3.9 ± 1.6, P value = 0.020) on Day 2 and significant NRS reductions for worst pain on Day 2 (P value = 0.045) and current pain on Day 2 (P value = 0.035) and Day 5 (P value = 0.020) compared to morphine. Patient satisfaction, adverse events, and adverse drug reactions were similar for both groups. Conclusions. For Asian patients with cancer pain, IV oxycodone is faster acting and showed similar analgesic efficacy and safety profiles as IV morphine. This trial is registered with Clinicaltrials.gov NCT02660229. |
| format | Article |
| id | doaj-art-f222325a96d642f6bc64030d71abc09c |
| institution | Kabale University |
| issn | 1203-6765 1918-1523 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pain Research and Management |
| spelling | doaj-art-f222325a96d642f6bc64030d71abc09c2025-02-03T01:26:47ZengWileyPain Research and Management1203-67651918-15232017-01-01201710.1155/2017/97417299741729Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control StudyKyung-Hee Lee0Jung-Hun Kang1Ho-Suk Oh2Moon-Ki Choi3Byoung-Yong Shim4Young-Jun Eum5Hye-Jeong Park6Jin-Hyong Kang7Department of Hematology/Oncology, Yeungnam University Hospital, Daegu, Republic of KoreaDepartment of Internal Medicine, Gyeongsang National University Hospital, Jinju, Republic of KoreaDepartment of Hematology/Oncology, Gangneung Asan Hospital, Gangneung, Republic of KoreaCenter for Colorectal Cancer, National Cancer Center, Ilsan, Republic of KoreaDepartment of Medical Oncology, St. Vincent’s Hospital, Suwon, Republic of KoreaDepartment of Medical Affairs, Mundipharma Korea Ltd, Seoul, Republic of KoreaDepartment of Medical Affairs, Mundipharma Korea Ltd, Seoul, Republic of KoreaDepartment of Medical Oncology, Seoul St. Mary’s Hospital, Seoul, Republic of KoreaObjective. To compare efficacy and safety of intravenous continuous infusion of oxycodone with morphine in patients with cancer pain. Methods. A 5-day, randomized, open-label, exploratory study at 6 sites in the Republic of Korea. Sixty-six adults aged ≥19 years with moderate-to-severe cancer pain (Numeric Rating Scale [NRS] ≥ 4) were enrolled. The study group received intravenous (IV) oxycodone, and the comparator group received IV morphine which were titrated depending on pain intensity. The efficacy endpoint is change in average NRS score from baseline to Day 5. Other assessments included worst, current, and average pain intensity; patient satisfaction; medication dose; and adverse events. Results. Both groups achieved >50% reduction in average pain intensity: from “moderate” at baseline (oxycodone versus morphine: 6.0 ± 1.8 versus 5.9 ± 1.4) to “mild” at Day 5 (2.5 ± 1.8 versus 2.8 ± 1.6). While this reduction was similar between groups (3.5 ± 2.2 versus 3.1 ± 1.8, P value = 0.562), oxycodone achieved faster pain relief (average pain: 3.0 ± 1.6 versus 3.9 ± 1.6, P value = 0.020) on Day 2 and significant NRS reductions for worst pain on Day 2 (P value = 0.045) and current pain on Day 2 (P value = 0.035) and Day 5 (P value = 0.020) compared to morphine. Patient satisfaction, adverse events, and adverse drug reactions were similar for both groups. Conclusions. For Asian patients with cancer pain, IV oxycodone is faster acting and showed similar analgesic efficacy and safety profiles as IV morphine. This trial is registered with Clinicaltrials.gov NCT02660229.http://dx.doi.org/10.1155/2017/9741729 |
| spellingShingle | Kyung-Hee Lee Jung-Hun Kang Ho-Suk Oh Moon-Ki Choi Byoung-Yong Shim Young-Jun Eum Hye-Jeong Park Jin-Hyong Kang Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study Pain Research and Management |
| title | Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study |
| title_full | Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study |
| title_fullStr | Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study |
| title_full_unstemmed | Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study |
| title_short | Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study |
| title_sort | intravenous oxycodone versus intravenous morphine in cancer pain a randomized open label parallel group active control study |
| url | http://dx.doi.org/10.1155/2017/9741729 |
| work_keys_str_mv | AT kyungheelee intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT junghunkang intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT hosukoh intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT moonkichoi intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT byoungyongshim intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT youngjuneum intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT hyejeongpark intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy AT jinhyongkang intravenousoxycodoneversusintravenousmorphineincancerpainarandomizedopenlabelparallelgroupactivecontrolstudy |